President of Evidera Karen Kaucic, MD, said, “Through Medimix we will have rapid and efficient access to an extended and robust pool of global clinician and patient-level information to enhance client business decisions.”
This includes forecasting, marketing, commercial analytics, business intelligence, health economics, medical affairs, strategy, and licensing.
“It also will offer the opportunity to leverage data ownership in key therapeutic areas – oncology, for example – to gain enterprise experience and additional knowledge that can be applied across offerings and client engagements,” Kaucic explained.
Medimix’s proprietary cloud-based visualization and analytics interface “scans, extracts, and synthesizes big data and evidence-based information,” according to the company. It draws on a database of 2.2m health care providers with a focus on hematology and oncology.
The company’s primary solution, LiveTracker, monitors therapeutic markets and drugs in real time, providing RWE in more than 60 countries, including information about market structure, drug awareness and adoption levels, as well as patient profiles, treatment sequencing, and outcomes.
